In T2D, 14,292 (45.1%) recorded purchases of second-line treatments and 6,861 (22.9%) progressed to use insulin (Table 1; for EstBB and UKBB, see Supplementary Table 2). This evidence concerns the gene INS and type 2 diabetes mellitus.